AbbVie reported a 10% revenue increase in Q4 driven by strong sales of Skyrizi and Rinvoq, offsetting declines in Humira. Pfizer saw a 1.16% revenue decline due to COVID-related drops in key products but is investing heavily in obesity drug development with acquisitions and partnerships. AbbVie’s established immunology portfolio supports steady income and dividend growth, while Pfizer’s future depends on successful pipeline execution, especially in obesity treatments. Both companies face risks but have distinct growth strategies: AbbVie on proven drugs and Pfizer on pipeline potential.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
